subject: Parkinson's Disease – Pipeline Assessment and Market Forecasts to 2016 Report added in Vision Shopsters [print this page] Parkinson's Disease Pipeline Assessment and Market Forecasts to 2016 Report added in Vision Shopsters
The industry analysis specialist's new report, "Parkinson's Disease Pipeline Assessment and Market Forecasts to 2016" is an essential source of information and analysis on the global Parkinson's disease market. The report identifies the key trends shaping and driving the global Parkinson's disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Parkinson's disease sector. GlobalData estimated the global Parkinson's disease market to be valued at $3,178m in 2009. It is forecast to grow at 0.9% annually for the next seven years to reach $3,384m by 2016. This low growth is ascribed to patent expirations, subsequent entry of generics, weak developmental pipeline and the unknown cause of the disease continues to pose significant challenges for prospective market entrants, is expected to keep the market static. Ageing population would be a key driver of this market. The global Parkinson's disease market is not well served with current product options and boundless scope is available to new entrants that would capture value from underserved segments. Designing disease-modifying drugs rather than drugs for providing symptomatic relief is one of the key challenges of this market and could provide significant market for any company. GlobalData finds that the global Parkinson's disease market is increasingly hampered by lack of innovation. On the whole, the late stage pipeline consists of drugs that are aimed at the symptomatic treatment of the disease. There are 181 products in different developmental stages in 2010. Majorly, pipeline presents drugs that are aimed at symptomatic treatment of the disease. Balancing the pipeline with the huge burden of the disease and high expectations of patients, the pipeline is considered to be weak. If a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects such as dyskinesis, psychiatric side effects and obsessive compulsive behaviors. Currently, these are the biggest challenges preventing most pipeline products from capturing these unmet needs.
Scope
The scope of the report includes:
- Annualized global Parkinson's disease market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes dopamine agonists, adenosine receptor antagonists, serotonin receptor targetters, glutamate receptor antagonists, NMDA receptor targetters, AMPA receptor antagonists, stem cell and gene therapy.
- Analysis of the current and future market competition in the global Parkinson's disease market. Key future market players covered are Merck Serono, Acadia Pharmaceuticals, Axxonis Pharma AG, Avicena Group Inc., and Solvay Pharmaceuticals.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with Parkinson's disease.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Parkinson's disease market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Parkinson's disease market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Parkinson's disease market landscape? Identify, understand and capitalize.
Companies Mentioned
Merck Serono
Acadia Pharmaceuticals
Axxonis Pharma AG
Avicena Group Inc.
Solvay Pharmaceuticals
Impax Laboratories
To know more about this report & to buy a copy please visit :
